Plain-English translation of NCT06158269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether daratumumab combined with three other medications (bortezomib, lenalidomide, and dexamethasone) can effectively treat newly diagnosed multiple myeloma that has aggressive genetic features. Multiple myeloma is a cancer of blood-forming cells in the bone marrow. This medication combination is designed to be given before and after a stem cell transplant procedure, with the goal of putting your disease into remission.
Patients with multiple myeloma that has aggressive genetic abnormalities (called 'double-hit') tend to have worse outcomes with standard treatments. This trial is testing whether adding daratumumab to the standard treatment combination can improve survival and help more patients achieve deeper remissions.
You likely qualify if…
You likely don't qualify if…
You would receive the four-drug combination intravenously and orally for four cycles (about 4 months), followed by a stem cell transplant. After transplant recovery, you would receive four more cycles of the same combination as consolidation therapy. Then, depending on how well your disease responds (measured by special blood tests), you would enter a maintenance phase on either one medication or the full four-drug combination for up to two years. You would have regular blood tests and monitoring appointments throughout the study.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~40 participants
Started
December 2023
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lugui Qiu
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.